Resona Asset Management Co. Ltd. reduced its position in Gilead Sciences, Inc. (NASDAQ:GILD – Free Report) by 2.6% in the 3rd quarter, HoldingsChannel.com reports. The firm owned 390,084 shares of the biopharmaceutical company’s stock after selling 10,543 shares during the period. Resona Asset Management Co. Ltd.’s holdings in Gilead Sciences were worth $58,325,000 at the end of the most recent reporting period.
Other institutional investors also recently bought and sold shares of the company. PFS Partners LLC lifted its stake in Gilead Sciences by 101.1% in the 3rd quarter. PFS Partners LLC now owns 191 shares of the biopharmaceutical company’s stock valued at $28,000 after buying an additional 96 shares in the last quarter. Persistent Asset Partners Ltd purchased a new stake in shares of Gilead Sciences in the second quarter valued at $25,000. Laurel Wealth Advisors LLC acquired a new stake in shares of Gilead Sciences during the third quarter valued at $29,000. Kimelman & Baird LLC acquired a new position in Gilead Sciences in the 2nd quarter valued at about $25,000. Finally, Toth Financial Advisory Corp lifted its holdings in Gilead Sciences by 85.5% in the 3rd quarter. Toth Financial Advisory Corp now owns 217 shares of the biopharmaceutical company’s stock valued at $32,000 after purchasing an additional 100 shares in the last quarter. 83.67% of the stock is currently owned by hedge funds and other institutional investors.
Gilead Sciences Price Performance
Shares of NASDAQ GILD opened at $166.33 on Friday. Gilead Sciences, Inc. has a fifty-two week low of $116.88 and a fifty-two week high of $176.58. The firm’s 50-day simple moving average is $157.26 and its 200 day simple moving average is $142.46. The company has a quick ratio of 1.22, a current ratio of 1.38 and a debt-to-equity ratio of 1.84. The stock has a market cap of $206.30 billion, a P/E ratio of -52.64 and a beta of 0.35.
Gilead Sciences (NASDAQ:GILD – Get Free Report) last released its earnings results on Thursday, October 29th. The biopharmaceutical company reported $2.55 EPS for the quarter, beating the consensus estimate of $2.19 by $0.36. Gilead Sciences had a negative net margin of 12.47% and a negative return on equity of 1.85%. The firm had revenue of $8.30 billion for the quarter, compared to analysts’ expectations of $7.81 billion. During the same quarter last year, the company earned $2.47 EPS. Gilead Sciences’s quarterly revenue was up 6.8% on a year-over-year basis. Equities analysts expect that Gilead Sciences, Inc. will post -0.97 EPS for the current year.
Gilead Sciences Announces Dividend
The business also recently announced a quarterly dividend, which will be paid on Wednesday, December 30th. Stockholders of record on Tuesday, December 15th will be issued a dividend of $0.82 per share. This represents a $3.28 annualized dividend and a dividend yield of 2.0%. The ex-dividend date of this dividend is Tuesday, December 15th. Gilead Sciences’s dividend payout ratio is currently -103.80%.
Wall Street Analysts Forecast Growth
Several analysts have commented on the company. Bank of America lifted their price target on Gilead Sciences from $168.00 to $172.00 and gave the company a “buy” rating in a report on Tuesday, October 20th. HSBC upped their price target on Gilead Sciences from $155.00 to $175.00 and gave the stock a “buy” rating in a research note on Thursday, September 10th. Needham & Company LLC set a $175.00 target price on shares of Gilead Sciences in a research report on Friday, October 30th. Scotiabank lifted their price target on shares of Gilead Sciences from $177.00 to $200.00 and gave the company a “sector outperform” rating in a research report on Friday, October 30th. Finally, Wall Street Zen upgraded shares of Gilead Sciences from a “hold” rating to a “buy” rating in a research note on Saturday, September 19th. Twenty-three equities research analysts have rated the stock with a Buy rating and six have issued a Hold rating to the company. According to MarketBeat.com, Gilead Sciences has a consensus rating of “Moderate Buy” and an average target price of $171.63.
View Our Latest Research Report on GILD
Insider Buying and Selling
In other Gilead Sciences news, CFO Andrew D. Dickinson sold 3,000 shares of the company’s stock in a transaction dated Monday, November 16th. The shares were sold at an average price of $171.47, for a total transaction of $514,410.00. Following the completion of the sale, the chief financial officer directly owned 158,096 shares of the company’s stock, valued at approximately $27,108,721.12. This represents a 1.86% decrease in their ownership of the stock. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available through this hyperlink. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, insider Johanna Mercier sold 28,000 shares of the business’s stock in a transaction on Monday, November 16th. The shares were sold at an average price of $170.55, for a total transaction of $4,775,400.00. Following the sale, the insider directly owned 110,684 shares in the company, valued at approximately $18,877,156.20. This trade represents a 20.19% decrease in their ownership of the stock. The SEC filing for this sale provides additional information. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. In the last three months, insiders sold 237,709 shares of company stock valued at $39,799,137. 0.30% of the stock is currently owned by company insiders.
About Gilead Sciences
Gilead Sciences, Inc. is a biopharmaceutical company that discovers, develops and commercializes medicines for serious diseases. Founded in 1987 and headquartered in Foster City, California, the company focuses on antiviral therapies, including treatments and preventive medicines for HIV and medicines for viral hepatitis. Its products include Biktarvy for HIV and Epclusa for hepatitis C. Gilead also develops medicines in areas such as oncology and inflammatory diseases. Its portfolio includes Veklury (remdesivir), an antiviral medicine used to treat COVID-19.
Read More
- Five stocks we like better than Gilead Sciences
- Anthropic’s Record IPO Could Ease a Major Concern for Broadcom Investors
- MarketBeat Week in Review – 11/16 – 11/20
- Survey Reveals: How Much Would People Pay for Ribeye Before Giving It Up? [2026]
- If NVIDIA Tightens Its Wallet, These 3 Stocks Could Feel It
Want to see what other hedge funds are holding GILD? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Gilead Sciences, Inc. (NASDAQ:GILD – Free Report).
Receive News & Ratings for Gilead Sciences Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Gilead Sciences and related companies with MarketBeat.com's FREE daily email newsletter.
